Jørgensen Rasmus Wejnold, Anderson Kiran Annette, Odgaard Anders, Jensen Claus Hjorth
Department of Orthopaedic Surgery, Herlev-Gentofte University Hospital of Copenhagen, Hand Clinic, Copenhagen, Denmark.
Department of Orthopaedics, Herlev-Gentofte University Hospital of Copenhagen, Hand Clinic, Copenhagen, Denmark.
J Wrist Surg. 2022 Nov 28;12(4):324-330. doi: 10.1055/s-0042-1757766. eCollection 2023 Aug.
New and improved surgical techniques are warranted to treat osteoarthritis of the thumb carpometacarpal joint (CMC-1). The Pyrocardan implant yields striking results but only few series exist, making the evidence scarce. The aim of this study was to conduct a prospective series using the Pyrocardan implant. We compared the outcomes to a matched historical control group of patients operated on with ligament reconstruction and tendon interposition. The hypothesis was that the Pyrocardan implant would yield better patient-reported outcomes as well as the procedure would be safe and effective in relieving symptoms of CMC-1 osteoarthritis. In total, 30 patients were included in the prospective series. These 30 patients were compared, in a 1:3 design, to a matched historical group. Results were promising with visual analogue scale scores of 0.7 (rest) and 2.1 (function), key-pinch score of 5.1 kg, and shortened Disability of the Arm, Shoulder, and Hand score of 14.3 after 1 year when using the Pyrocardan implant. The revision rate was 10%. We found no evidence of subsidence of the thumb. We found no differences in patient-reported outcomes between the two groups. In conclusion, the Pyrocardan implant is a viable option in the treatment of CMC-1 osteoarthritis but with a significant revision rate. When comparing the Pyrocardan implant to a historical control group, we failed to find any differences in patient-reported outcomes. IV - case series.
需要新的和改进的手术技术来治疗拇指腕掌关节(CMC-1)骨关节炎。Pyrocardan植入物取得了显著效果,但仅有少数系列报道,证据不足。
本研究的目的是使用Pyrocardan植入物进行前瞻性系列研究。
我们将结果与一组采用韧带重建和肌腱间置术的匹配历史对照组患者进行比较。假设是Pyrocardan植入物将产生更好的患者报告结局,并且该手术在缓解CMC-1骨关节炎症状方面将是安全有效的。前瞻性系列研究共纳入30例患者。这30例患者按照1:3的设计与匹配的历史组进行比较。
使用Pyrocardan植入物1年后,视觉模拟量表评分为0.7(休息时)和2.1(功能时),关键捏力评分为5.1千克,手臂、肩部和手部残疾评分缩短至14.3,结果令人满意。翻修率为10%。我们未发现拇指下沉的证据。我们发现两组患者报告的结局无差异。
总之,Pyrocardan植入物是治疗CMC-1骨关节炎的一个可行选择,但翻修率较高。将Pyrocardan植入物与历史对照组进行比较时,我们未发现患者报告的结局有任何差异。
IV - 病例系列。